Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer
J Clin Oncol. 2015 Apr 10;33(11):1243-51. doi: 10.1200/JCO.2014.59.1792. Epub 2015 Mar 2.
Sean O’Farrell , Hans Garmo , Lars Holmberg , Jan Adolfsson , Pär Stattin , Mieke Van Hemelrijck
CARDIONCOLOGY.ORG ABSTRACT:
Data from 41,362 men who were treated for prostate cancer (PCa) were studied in order to clarify the link between risk of cardiovascular disease (CVD) and duration and type of androgen-deprivation therapy (ADT).
Results support the need for a solid indication for ADT in men with PCa so that benefit outweighs potential harm, particularly in men with a recent history of CVD.
© All rights reserved
image source: https://www.sciencedirect.com/science/article/abs/pii/S0960076014000867